Consensus Centessa Pharmaceuticals plc

Equities

CNTA

US1523091007

Real-time Estimate Cboe BZX 13:03:07 2024-04-30 EDT 5-day change 1st Jan Change
9.31 USD +0.22% Intraday chart for Centessa Pharmaceuticals plc -1.22% +16.65%

Evolution of the average Target Price on Centessa Pharmaceuticals plc

Price target over the last 5 years

History of analyst recommendation changes

98f7bf626cc10a6dee69bc60bdf8.O8F_GlVakhjU917QHLE7EQtKvPptTZNLso6PHmeOczo.das6cjkTzUGmjg2JcudsRj4Cxpg-PeIi4_fAWRbNAghjoyxeHmPQb66Hbg~909dbb2140eadf63700b054655844f1a
Morgan Stanley Upgrades Centessa Pharmaceuticals to Equalweight From Underweight, Doubles Price Target to $8 From $4 on 'Encouraging' Preclinical Data on Narcolepsy Treatment Candidate MT
Guggenheim Adjusts Price Target on Centessa Pharmaceuticals to $10 From $9, Maintains Buy Rating MT
Goldman Sachs Adjusts Price Target on Centessa Pharmaceuticals to $5 From $4.50, Maintains Neutral Rating MT
BMO Capital Adjusts Centessa Pharmaceuticals Price Target to $15 From $11, Maintains Outperform Rating MT
Evercore ISI Initiates Centessa Pharmaceuticals at Outperform Rating MT
Guggenheim Initiates Centessa Pharmaceuticals at Buy With $9 Price Target MT
SVB Securities Initiates Centessa Pharmaceuticals at Outperform With $6 Price Target MT
Morgan Stanley Adjusts Price Target on Centessa Pharmaceuticals to $4 From $5, Maintains Underweight Rating MT
Morgan Stanley Double Downgrades Centessa Pharmaceuticals to Underweight From Overweight, Adjusts Price Target to $5 From $10 MT
BMO Capital Adjusts Centessa Pharmaceuticals' Price Target to $11 from $19, Keeps Outperform Rating MT
Goldman Sachs Adjusts Centessa Pharmaceuticals' Price Target to $4 From $5, Keeps Neutral Rating MT
Morgan Stanley Adjusts Price Target for Centessa Pharmaceuticals to $10 From $15, Maintains Overweight Rating MT
BMO Capital Starts Centessa Pharmaceuticals at Outperform With $19 Price Target MT
Goldman Sachs Adjusts Centessa Pharmaceuticals' Price Target to $8 from $12, Keeps Neutral Rating MT
Morgan Stanley Adjusts Centessa Pharmaceuticals Price Target to $15 From $19, Maintains Overweight Rating MT
Morgan Stanley Trims Centessa Pharmaceuticals Price Target to $19 From $20, Maintains Overweight Rating MT
Goldman Sachs Starts Centessa Pharmaceuticals at Neutral, Maintains Price Target at $12 MT
Morgan Stanley Adjusts Centessa Pharmaceuticals' Price Target to $20 from $37, Keeps Overweight Rating MT
CENTESSA PHARMACEUTICALS : Jefferies Starts Centessa Pharmaceuticals at Buy With $35 Price Target MT
CENTESSA PHARMACEUTICALS : Morgan Stanley Starts Centessa Pharmaceuticals at Overweight With $37 Price Target MT
CENTESSA PHARMACEUTICALS : Goldman Sachs Starts Centessa Pharmaceuticals at Buy With $42 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
9.29 USD
Average target price
13.6 USD
Spread / Average Target
+46.39%
High Price Target
20 USD
Spread / Highest target
+115.29%
Low Price Target
8 USD
Spread / Lowest Target
-13.89%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Centessa Pharmaceuticals plc

Morgan Stanley
Guggenheim
Goldman Sachs
BMO Capital
Evercore ISI
SVB Securities LLC
Jefferies & Co.
  1. Stock Market
  2. Equities
  3. CNTA Stock
  4. Consensus Centessa Pharmaceuticals plc